FINWIRES · TerminalLIVE
FINWIRES

研究快讯:Snap:第一季度业绩符合预期;利润增长受阻,营收增速放缓

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:SNAP公布的第一季度营收为15.29亿美元(同比增长12%),符合预期;调整后EBITDA飙升至2.33亿美元(同比增长115%),超过市场普遍预期的2.15亿美元。自由现金流达到2.86亿美元(同比增长150%),表明营收增长已强劲转化为现金流。营收多元化策略取得成效,其他收入加速增长至2.85亿美元(同比增长87%),占总营收的19%,这主要得益于Snapchat+订阅和Memories Storage的普及。季度结束后,SNAP宣布裁员16%,取消300多个空缺职位,预计到年底将实现超过5亿美元的年度成本节约。用户指标反映了管理层优先发展高价值市场的战略,全球日活跃用户数 (DAU) 为 4.83 亿(增长 5%),而北美日活跃用户数下降至 9200 万(下降 7%),但北美平均每用户收入 (ARPU) 提升至 9.23 美元(增长 10%)。我们认为,此次重组将使 SNAP 更清晰地走上实现可持续 GAAP 盈利的道路,同时继续投资于高信心机遇,包括即将推出的 Specs 产品。

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661